Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Executive Summary
Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.
You may also be interested in...
M&A Activity Up Year-Over-Year, Driven By Tax-Inversion Deals And Diversification
The Actavis/Forest deal was the largest deal in the first quarter, but was among 62 deals in total that were signed in the biopharma sector during the quarter.
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.